Personalized tumor combination therapy optimization using the single-cell transcriptome

Chen Tang1, Shaliu Fu1,2, Xuan Jin1

  • 1Key Laboratory of Spine and Spinal Cord Injury Repair and Regeneration (Tongji University), Ministry of Education, Orthopaedic Department of Tongji Hospital, Frontier Science Center for Stem Cell Research, Bioinformatics Department, School of Life Sciences and Technology, Tongji University, Shanghai, China.

Genome Medicine
|December 2, 2023
PubMed
Abstract

Insights

This study introduces comboSC, a computational tool that uses single-cell transcriptomes to predict optimal personalized cancer drug combinations. It analyzes the immune microenvironment to identify synergistic therapies, accelerating personalized cancer treatment.

Area of Science:

  • Computational Biology
  • Genomics
  • Cancer Research

Background:

  • Personalized cancer treatment relies on precise characterization of tumors and immune microenvironments.
  • Current methods like in vitro assays or bulk transcriptomes overlook tumor heterogeneity and in vivo immune microenvironments.
  • Single-cell transcriptomes are crucial for overcoming these limitations in personalized cancer therapy.

Purpose of the Study:

  • To present comboSC, a computational proof-of-concept for optimizing personalized cancer combination therapy.
  • To stratify patient samples by evaluating their immune microenvironment using single-cell RNA sequencing.
  • To identify synergistic drug combinations and immunotherapy pairings for personalized clinical use.

Main Methods:

  • comboSC utilizes single-cell RNA sequencing data to quantitatively assess the immune microenvironment.
  • It integrates in vitro cellular response data to identify synergistic drug combinations.
  • Bipartition graph optimization is employed to prioritize drug combinations for clinical use.

Main Results:

  • comboSC was applied to 119 single-cell transcriptome datasets from 15 cancer types.
  • Predicted drug combinations were validated using literature, clinical trial data, cell line perturbations, and in vivo samples.
  • The study demonstrates the feasibility of comboSC for predicting effective cancer drug combinations.

Conclusions:

  • comboSC is a feasible computational prototype for predicting personalized cancer drug combinations.
  • It accelerates personalized tumor treatment by reducing screening time and saving clinical time.
  • A web server and source code are available for clinical and research users.

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K